Maven Securities’s iTeos Therapeutics ITOS Stock Holding History

Maven Securities’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,924	Closed	-$844K	–	1227
2020 Q4	$844K	Buy	+24,924	New	+$660K	0.08%	273

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Maven Securities's ITOS Position: Q1 2021 in Review

Maven Securities sold out of iTeos Therapeutics (ITOS) in Q1 2021, closing a stake of 24,924 shares — an estimated $844K sold.

Maven Securities first reported a position in ITOS in Q4 2020 and held it in 1 quarter. The position peaked at $844K in Q4 2020. 81 funds tracked by Wall St. Rank hold ITOS as of Q1 2021.

Maven Securities reported no remaining iTeos Therapeutics position as of Q1 2021 after selling out during the quarter.
Maven Securities sold 24,924 iTeos Therapeutics shares in Q1 2021, an estimated $844K.
Maven Securities first reported a position in iTeos Therapeutics in Q4 2020 and held it in 1 quarter.
Maven Securities's iTeos Therapeutics position peaked at $844K in Q4 2020.
81 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.